As bortezomib inhibits inducible NF-κB activity in MM cells, but enhances constitutive NF-κB activity via activation of the canonical pathway, bortezomib-induced cytotoxicity cannot be completely attributed to inhibition of canonical NF-κB activity in MM because inhibition of both canonical and non-canonical pathways is necessary to efficiently block total activity [49,51]. The gene discussed is NFKB1; the disease is Miyoshi myopathy.